PDS Biotechnology announces publication of research, patent grant

PDS Biotechnology announced the publication of preclinical research and a patent granted by the United States Patent and Trademark Office that strengthen the foundation of the Company’s infectious disease vaccine platform Infectimune. Preclinical research published in Vaccines demonstrated that the recombinant protein influenza vaccine Flublok combined with Infectimune significantly promoted improved quantity and quality of potent multifunctional CD4 T cells when compared to infectious disease adjuvants. The research concluded that Infectimune is a leading candidate for use in the next generation of preventive vaccines that may provide more effective and broader protection than current vaccines allow. Infectimune is being used in PDS0202, the Company’s universal influenza vaccine intended to provide broad protection against multiple flu strains. Additionally, the USPTO granted U.S. Patent Number 11,904,015 titled, “Vaccine Compositions and Methods of Use,” directed to vaccine compositions employing the Infectimune platform and influenza antigens to elicit T cells and antibodies in February 2024. The patent protects compositions containing the Infectimune platform and influenza antigens and methods of using the Infectimune platform with pathogenic antigens generally.